- Home
- MIR vs ACAD Comparison
MIR vs ACAD Comparison
Compare MIR & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIR
- ACAD
- Stock Information
- Founded
- MIR 2005
- ACAD 1993
- Country
- MIR United States
- ACAD United States
- Employees
- MIR N/A
- ACAD N/A
- Industry
- MIR Industrial Machinery/Components
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- MIR Technology
- ACAD Health Care
- Exchange
- MIR Nasdaq
- ACAD Nasdaq
- Market Cap
- MIR 5.2B
- ACAD 4.3B
- IPO Year
- MIR N/A
- ACAD 2004
- Fundamental
- Price
- MIR $22.74
- ACAD $23.61
- Analyst Decision
- MIR Strong Buy
- ACAD Buy
- Analyst Count
- MIR 5
- ACAD 21
- Target Price
- MIR $23.00
- ACAD $29.30
- AVG Volume (30 Days)
- MIR 4.4M
- ACAD 1.9M
- Earning Date
- MIR 10-28-2025
- ACAD 11-05-2025
- Dividend Yield
- MIR N/A
- ACAD N/A
- EPS Growth
- MIR N/A
- ACAD 615.00
- EPS
- MIR 0.05
- ACAD 1.33
- Revenue
- MIR $886,000,000.00
- ACAD $1,018,885,000.00
- Revenue This Year
- MIR $8.46
- ACAD $14.01
- Revenue Next Year
- MIR $7.96
- ACAD $11.72
- P/E Ratio
- MIR $489.53
- ACAD $17.82
- Revenue Growth
- MIR 7.88
- ACAD 14.41
- 52 Week Low
- MIR $9.45
- ACAD $13.40
- 52 Week High
- MIR $23.58
- ACAD $26.65
- Technical
- Relative Strength Index (RSI)
- MIR 60.32
- ACAD 39.78
- Support Level
- MIR $20.98
- ACAD $23.70
- Resistance Level
- MIR $23.58
- ACAD $25.90
- Average True Range (ATR)
- MIR 0.76
- ACAD 0.74
- MACD
- MIR 0.18
- ACAD -0.33
- Stochastic Oscillator
- MIR 76.90
- ACAD 8.16
About MIR Mirion Technologies Inc.
Mirion Technologies Inc provides products, services, and software that allow customers to safely leverage the power of ionizing radiation for applications that benefit the health, safety, vitality, and technological progress of the human experience. The Company manages its operations through two segments: Nuclear & Safety and Medical. The Medical segment improves the quality and safety of cancer care delivery and supports applications across medical diagnostics and practitioner safety. The Nuclear & Safety segment powers advancements in nuclear energy and critical radiation safety, measurement and analysis applications across laboratories, research and other industrial markets such as defense.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.